Welcome on Biogroup corporate website
We are pleased to welcome you on our corporate Website dedicated to investors.
Biogroup was founded back in 1998 by Stéphane Eimer in Alsace (East of France). Since then, we have been growing significantly both organically and through selective acquisitions. Biogroup is now the undisputed leader on the Medical lab testing market.
The Group has reached in 2020 a new step in its history by expanding abroad, with the acquisition of CMA Medina in Belgium. In 2021, we have further expanded our operations and acquired subsidiaries in Spain with Cerba Internacional and Analyza.
Our European expansion has reinforced our commitment to our core corporate values. We are a Group founded by biologists and managed and led by biologists. We value entrepreneurial spirit and regional footprint and remain the closest possible to our patients. Our biologists are committed to deliver high quality standards for the benefit of both our medical community and our patients.
Our commitment to deliver the best-in-class testing infrastructure during the Covid-19 health crisis has established Biogroup at the heart of the public health system.
We are committed to continuing the development of the group, investing in the innovations of tomorrow to offer the best healthcare service to our patients while maintaining our economic efficiency for the benefit of our investors and associated biologists.
Event
Tuesday, September 16th, 2025
Biogroup will present its H12025 – financial statements
The conference call will take place on Tuesday, September 16th, 2025 at 2:00 pm CET time
Invite will be sent by email.
News
— September 8th, 2025
IGAS (French General Inspectorate for Social Affairs) published in mid-July 2025 a report titled “Pertinence et efficience des dépenses de biologie médicale”, outlining recommendations for the French medical biology sector in the coming years.
These are recommendations only, addressed to the Health and Finance Ministries. They are not binding decisions and if several of these recommendations could be followed by the French Authorities, this would require additional steps, including going through the legislative process, before any implementation.
Accordingly, to avoid any premature speculations, Biogroup will not comment on this document at this stage.
Nevertheless, in this context we would like to reiterate that Biogroup launched a transformation plan at the end of 2023 to harmonize its operating model and to strengthen profitability, already achieving 50% of this plan by the end of 2025.
Reflecting these robust results, two rating agencies (S&P and Fitch) upgraded Biogroup in mid-July 2025 (B/B3/B).
— June 27th, 2022
Isabelle Eimer to become President of Biogroup
The Biogroup group announces that Dr Isabelle Eimer, MD PhD, president of CAB SELAS, one of the group’s main SELAS, will take over the presidency and management of the Biogroup group. She succeeds Stéphane Eimer, who died suddenly on 22 June 2022.
Isabelle Eimer joined the group in 2005 and over the years has chaired several companies in the group founded and managed by Stéphane Eimer, and has been closely involved in all strategic decisions. With her extensive knowledge of the group, Isabelle Eimer intends to continue the development and activity of the family-owned Biogroup in the entrepreneurial spirit that has always driven the group of talents that Stéphane Eimer brought together.
Biogroup is managed by a solid and experienced team that has accompanied the company for several years. The Group will ensure that the governance evolves so that it can continue its development as the European leader in medical biology.
“Biogroup is a strong company with an ambitious development and an outstanding performance. I wish to preserve our strong entrepreneurial and family culture which has made Biogroup a fast-growing company, established in France and in Europe, and rich in its team of biologists for the greater benefit of patients and health”, declared Isabelle Eimer, President of Biogroup.